Skip to content
HowShorted

SpringWorks Therapeutics, Inc. short interest in 2021

In 2021, SpringWorks Therapeutics, Inc.'s disclosed short interest ran from 7.14% of shares outstanding on 15 Jan 2021 to 5.33% on 31 Dec 2021, a change of -1.81 percentage points. The year's high was 8.35% on 15 Apr 2021 and its low 5.33% on 31 Dec 2021, averaging 6.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.42 days on 28 May 2021. Full history: SpringWorks Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for SpringWorks Therapeutics, Inc. in 2021

2021 in figures

Start of year
7.14% (15 Jan 2021)
End of year
5.33% (31 Dec 2021)
Change
-1.81 pp
High
8.35% (15 Apr 2021)
Low
5.33% (31 Dec 2021)
Average
6.96%
Highest days to cover
23.42 (28 May 2021)
SEC filings marked
8

Every report in 2021

SpringWorks Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20217.14%11.06
29 Jan 20216.40%9.78
12 Feb 20216.23%13.87
26 Feb 20216.75%14.1210-K filed, results (8-K)
15 Mar 20217.02%6.32
31 Mar 20217.70%8.79
15 Apr 20218.35%16.12
30 Apr 20218.06%17.94
14 May 20217.72%17.9510-Q filed, results (8-K)
28 May 20217.75%23.42
15 Jun 20217.18%16.21
30 Jun 20217.08%11.28
15 Jul 20216.88%22.32
30 Jul 20216.77%13.52
13 Aug 20216.41%11.5910-Q filed, results (8-K)
31 Aug 20216.65%15.49
15 Sep 20216.37%12.49
30 Sep 20216.66%10.19
15 Oct 20217.58%9.01
29 Oct 20218.14%12.26
15 Nov 20216.91%12.4110-Q filed, results (8-K)
30 Nov 20216.02%9.66
15 Dec 20215.87%8.70
31 Dec 20215.33%6.81

See also: SpringWorks Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.